Elraglusib nearly doubles 1-year survival rates in PDAC clinical trial
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
News
Unusual glioma tumor case shows need for molecular testing
A young girl with an unusual form of low-grade glioma, a type of brain tumor, responded well to standard chemotherapy, emphasizing the value of…
Relacorilant delays ovarian cancer disease progression: Trial data
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
Patients in cell therapy Carvykti trial in remission after 5 years
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…
Mitochondria-targeting treatments for AML focus of research grant
A team led by a Rice University researcher received a grant to investigate treatments targeting mitochondria for acute amyloid leukemia (AML), a type of…
Technique for PDAC may help increase effects of chemotherapy
Combining chemotherapy with focused ultrasound and microbubbles is safe and helps deliver chemotherapy drugs more effectively to tumors in people with inoperable pancreatic ductal adenocarcinoma…
Glioblastoma treatment lucicebtide well tolerated in clinical trial
Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…
EU committee recommends Blenrep combos for approval in RRMM
A committee of the European Medicines Agency has recommended approving GSK’s Blenrep (belantamab mafodotin) in combination with other therapeutic agents to treat relapsed or refractory…
First patient dosed in Phase 1 trial testing AML T-cell treatment
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid…
PDAC antibody-drug conjugate EBC-129 wins FDA fast track status
U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…
